Serim Research Corporation – Trademark Portfolio
Entity Type: 03
Serim Research Corporation holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 40 (Treatment & Processing) across 4 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include SERIM and PYLORITEK. The owner is based in Elkhart, IN.
23575 County Road 106
Elkhart, IN 46514
Showing of trademarks Trademarks
Trademark Classifications
Serim Research Corporation's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Serim Research Corporation have?
Serim Research Corporation has 8 U.S. trademarks filed with the USPTO. Of these, 3 registered, 3 abandoned, 2 cancelled.
What trademark classes does Serim Research Corporation file in?
Serim Research Corporation files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Serim Research Corporation's most well-known trademarks?
Serim Research Corporation's registered trademark portfolio includes well-known marks such as SERIM and PYLORITEK. These are among 3 currently registered trademarks in the portfolio.
What is Serim Research Corporation's trademark registration success rate?
Serim Research Corporation has a 38% trademark registration rate, with 3 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.